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Introduction: Mucous plugging is associated with fatal asthma and may have a causative role
for non-fatal cases of severe acute asthma. However, mucolytic agents have not been found
effective in reversing the obstruction of acute asthma. We test the hypothesis that rhDNAse,
an agent that reduces viscoelasticity of sputum in patients with cystic fibrosis, has a thera-
peutic role in acute asthma.
Methods: Symptomatic asthmatics aged 18e55 years presenting to an Emergency Department
with an FEV1 < 60% predicted after 2 nebulized albuterol and ipratropium treatments were
included. Patients were randomized into one of three nebulized rhDNAse treatment groups
of2.5, 5.0 or 7.5 mg, or placebo. Standardized bronchodilator therapy was continued
throughout the protocol and the FEV1 at 6 h was the primary study endpoint.
Results: 50 patients were enrolled. There were no significant differences in FEV1% predicted
between the rhDNAse and placebo patients at any of the post-randomization time points.
The dose of rhDNAse administered did not influence response. In a post-hoc stratification,
patients with the lowest pre-randomization FEV1 tended to improve more from rhDNAse,l; ED, Emergency Department; FEV1, Forced expiratory volume in the first second of exhalation.
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rhDNAse in acute severe asthma 1097particularly at times 60 and 120 min post-randomization.
Conclusion: In this pilot study rhDNAse did not cause clinical improvement among severely ill
adults refractory to standardized care. The observed trend to higher FEV1 among the most
severely obstructed patients is an exploratory finding that may warrant further study.
This clinical trial was registered as NCT00169962 under the name “Study of Pulmozyme to
Treat Severe Asthma Episodes”.
ª 2012 Elsevier Ltd. All rights reserved.Introduction
Airway obstruction in severe acute asthma can be caused
by bronchoconstriction, airway edema, and mucous plug-
ging. Bronchoconstriction is typically treated with short
acting beta-agonists, inhaled anticholinergics and when
severe, intravenous magnesium sulfate.1,2 Systemic
steroids are used to treat airway edema and inflammation,
although benefit in adults is not always noted during the
Emergency Department (ED) treatment period. In spite of
bronchodilator and prednisone based ED therapy, of the 1.8
million annual ED visits for asthma in the USA nearly
500,000 hospitalizations still occur.3 This is in addition to
4200 annual deaths attributed to asthma.3
Fatal asthma is typically characterized by exudative
airway luminal obstruction with extensive plugging that is
very difficult to reverse.4 Presumably patients with severe
acute asthma who do not respond to bronchodilators are
more likely to have acute and subacute mucous plugging
contributing to airway obstruction. The pathologic findings
are consistent with the observation that shorter durations
of asthma worsening respond more quickly to bronchodi-
lators than longer durations.5
Mucoactive agents to enhance clearance of mucin-
related secretions have been investigated for acute
severe asthma without clear evidence of efficacy, and
NAEPP asthma guidelines do not recommend mucolytics to
reverse airway plugging.6 Aerosolized rhDNAse is an FDA
approved agent for cystic fibrosis used to alleviate airway
obstruction from viscous secretions.7 Several anecdotal
reports have found rhDNAse effective in reversing mucous
plugging in either intubated patients or non-intubated
patients refractory to beta-agonists.8e10 However, in the
only published clinical trial evaluating the efficacy of
rhDNAse, acutely ill asthmatic children with moderate to
severe exacerbations did not show benefit.11
Our objective was to determine if aerosolized rhDNAse
was a useful adjunct in non-intubated adult ED asthmatics
with very severe acute obstruction refractory to nebulized
bronchodilators. We evaluated 1) whether rhDNAse
improved pulmonary function in acute severe asthma 2)
whether increasing doses of rhDNAse provided greater
improvement in pulmonary function, 3) the relationship
between illness severity and response to rhDNAse and 4)
safety of rhDNAse in acute asthma.
Methods
The study was conducted in the Emergency Department
(ED) at Long Island Jewish Medical Center, a voluntaryteaching hospital. Inclusion criteria were patients ages
18e55 years with acute asthma worsening, a 6 month or
longer history of known asthma, and a forced expiratory
volume in 1 s (FEV1) less than 60% of predicted at both ED
entry and 40 min after two sets of standardized asthma
treatments (see trial design below). Patients with the
following were excluded: greater than 15 pack-year history
of smoking; pregnant or breast feeding; a need for intu-
bation before randomization; pneumonia; chronic lung
disease other than asthma; any other clinically significant
medical conditions that could in the opinion of the inves-
tigator increase the risk of adverse effects with treatment.
Additionally, patients had to be willing and able to perform
spirometry maneuvers, stay in the ED for at least 6 h, and
then participate in a follow-up visit in 24 h.
Trial design and treatment
Upon ED arrival patients underwent spirometry and a brief
clinical assessment followed by treatment with 5.0 mg
nebulized albuterol, 0.5 mg nebulized ipratropium, and
either 60 mg oral prednisone or 125 mg intravenous meth-
ylprednisilone. For patients with an initial FEV1 < 25%
predicted 2 g of magnesium sulfate was infused intrave-
nously over 10 min. After the initial bronchodilator treat-
ment was completed (approximately 20 min after ED
entry), spirometry was repeated and a second course of
5.0 mg nebulized albuterol and 0.5 mg nebulized ipra-
tropium given. After completion of this second bronchodi-
lator treatment spirometery was repeated and patients
with an FEV1 < 60% who met study inclusion criteria were
randomized to receive study interventions or placebo.
This was a dose ranging study where a total of 50 patients
were randomized 3:2 to receive double-blind, single-dose
treatment with 2.5mg of nebulized rhDNAse or placebo (first
17 patients); 5.0 mg nebulized rhDNAse or placebo (next 17
patients), or 7.5 mg nebulized rhDNAse or placebo (final 16
patients) (Fig. 1). Therefore a total of 30 patients received
a single dose of rhDNAse and 20 patients received a like
quantity of placebo sterile saline. After study drug admin-
istration the standardized treatment protocol continued,
with patients receiving 2.5 mg albuterol and 0.5 mg ipra-
tropium at time 40 min; additional 2.5 mg albuterol treat-
ments were administered at time 60 min and hourly until
360 min after ED arrival. All inhaled treatments were given
by a disposable hand held nebulizer driven by a 7 L 100%
oxygen flow, and administered directly by mouthpiece. Over
the 360 min protocol each patient received a total of
22.5 mg of albuterol and 1.5 mg of ipratropium.
At the 360 min ED assessment (approximately 320 min
after trial drug administration), the investigator evaluated
Figure 1 CONSORT diagram of enrolled patients.
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admission. Clinicians were asked to adhere to NAEPP
consensus guidelines for determining need for hospitaliza-
tion, and to further provide consistency the protocol rec-
ommended hospitalization for a final FEV1 < 50% predicted,
although the treating clinician had the final disposition
decision. 24 h after enrollment, patients had repeat clinical
assessments which included spirometry and recording of
any adverse events. A follow-up telephone contact was
made 7 days after trial treatment ended, and patients
described any additional urgent or emergent need for
medical care since the 24 h assessment.
rhDNAse and placebo nebules were identical in appear-
ance and equal in volume, and both the patient and
investigator were blinded to the intervention. Randomiza-
tion schemes were computer generated by the hospital
pharmacy. Written informed consent was obtained from all
patients and the study was approved by the investigational
review board of the North Shore-LIJ Medical Center.
Spirometry methods were based on American Thoracic
Society/European Respiratory Society criteria with modifi-
cations made for a trial population of acutely ill
subjects.12,13 Spirometry was performed using the KoKo
Spirometer (Pulmonary Data Services, Lewisville, Colo),
with real-time feedback provided to ensure compliance
with study performance criteria. Measured value-
acceptability criteria for patient maneuvers included
a forced expiratory effort of at least 2 s, a back-
extrapolated volume of <5%, and a peak flow rate within
the first 120 ms of forced expiration. Three or more efforts
were obtained at each assessment. FEV1 values were
considered reproducible if the two best efforts were within
10% of each other. An additional criteria, absence of glottic
closure in the first second, was evaluated when timeeflowgraphs were inspected visually. Other clinical assessments
included peak flow rate, respiratory rate, use of accessory
muscle usage (sternocleidomastoid muscle groups, yes/no)
and a modified Borg scaled dyspnea index which utilized
a numeric scoring system (10 Z most severe dyspnea,
0 Z none) along with visual cues.
Statistical analysis
This study was designed to explore the efficacy, tolerability
and safety of rhDNAse in an acutely ill ED population. FEV1%
predicted at 6 h after ED arrival was the primary endpoint.
In addition we performed a number of planned exploratory
analyses to test several hypotheses. This included deter-
mining whether rhDNAse improved FEV1 at a number of
post-randomization time points; determining whether
higher rhDNAse doses led to greater improvement; and
determining whether patients with the lowest FEV1 were
more likely to respond to rhDNAse. Since the study was set
up as exploratory, power analyses were not used to deter-
mine the sample size.
Unadjusted Student’s t-tests were used to compare FEV1
% predicted for the primary 360 min hour endpoint and for
each of the post-randomization time points(time 60,120,
180, 240 and 360 min after ED arrival). The post-
randomization FEV1 % predicted data were then adjusted
for the pre-randomization FEV1 (time 40 min) to control for
variability in the initial measurement. To test whether
severity of illness influenced the drug effect, patients were
split into 2 groups according to the pre-randomization (time
40 min) median FEV1 % predicted value. The model included
treatment group (drug), time 40 min FEV1 % predicted
(severity), and the interaction between drug and severity
(drug*severity) for each of the time points.
Table 2 Average FEV1% predicted (unadjusted).
Time
(minutes)
rhDNAse FEV1%
predicted(N Z 30)
placebo FEV1 %
predicted (N Z 20)
0 28.2 30.1
20 35.1 36.5
40 38.4 39.0
60 40.9 42.7
120 43.6 45.6
180 47.0 45.7
240 47.9 45.8
360 47.0 47.5
24 HR 39.6 43.8
rhDNAse or placebo was administered at time 40 min.
Comparing FEV1 at each time point, all p values > 0.05.
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Fifty patients were enrolled and clinical characteristics are
described in Table 1. The placebo and rhDNAse subjects
were similar for age, gender and past asthma history as well
as FEV1 % predicted on ED arrival. Other clinical parameters
appeared similar for the rhDNAse and standard care groups
on ED arrival, including peak flow (38.9% versus 39.2%
predicted), minute respiratory rate (21.9 versus 20.0) and
frequency of accessory muscle/sternocleidomastoid usage
(79% versus 65%). Both groups had a similar response to the
pre-randomization bronchodilator treatments given at time
0 and 20 min, and at time 40 min the FEV1 was 38.4% pre-
dicted in the rhDNAse group and 39.0% predicted in the
standard care group.
Table 2 presents the FEV1 % predicted for the placebo
and rhDNAse groups at all study time points. The FEV1 at
360 min was similar in the placebo and rhDNAse groups
(p > 0.05) as well as for all other post-randomization time
points. Data was then adjusted for the pre-intervention
FEV1 (time 40 min) and shown in Fig. 2. Again, there were
no differences in FEV1 between placebo and rhDNAse
groups at any of the post-randomization time
points(p > 0.05). Subjective dyspnea symptoms were
assessed by a modified Borg scale, with 10 representing the
most severe dyspnea and 0 representing no dyspnea
symptoms. There were no significant differences between
the 2 groups at any of the post-randomization points (data
not shown), and at time 360 min the Borg score in the
placebo group was 2.7 and in the rhDNAse group was 3.4
(pZ ns), There weren’t any significant differences in heart
or respiratory rates at any of the post-randomization time
points (data not shown).Table 1 Patient characteristics at ED presentation.
rhDNAse
(N Z 30)
placebo
(N Z 20)
Demographic characteristics:
Age in years, mean (SD) 41.3 (9.7) 36.0 (10.2)
Female, n (%) 21 (70%) 15 (75%)
Race/Ethnicity, n (%)
White 4 (13.3%) 1 (5%)
Black 18 (60%) 9 (45%)
Asian 2 (6.7%) 1 (5%)
Hispanic 3 (10%) 6 (30%)
Other 3 (10%) 3 (15%)
Asthma history:
ED visits past 1 yr
(median,range)
1.0 (0e5) 1.0 (0e10)
Hospitalizations past 5 yrs
(median,range)
0.0 (0e6) 0.0 (0e12)
Previous intubations, n (%) 6 (20%) 4 (20%)
ICU asthma visits
past 5 yrs, n (%)
0 (0%) 1 (5%)
Inhaled steroid usage past
6 months, n (%)
8 (30.8%) 5 (35.7%)
Smoker (current or
previous), n (%)
11 (36.7%) 13 (65.0%)
No. of yrs with asthma,
mean (SD)
22.8 (14.9) 20.7 (14.2)To explore whether more severe obstruction predicted
response to therapy, Table 3 shows data grouped by the
pre-randomization (time 40 min) FEV1 above and below 39%
(the median value). Patients with a FEV1  39% predicted
had responses in favor of the drug at time 60 min
(pZ 0.045) and 120 min (pZ 0.039). The time 180, 240 and
360 min p values were greater than 0.05 at these later time
points. When adjustment for multiple comparisons were
performed, significance was lost at all time points.
Fig. 3 indicates the differences in FEV1 at the post-
intervention time points for each of the three rhDNAse
doses when compared to the placebo group. There was no
clear pattern of a dose-related effect. A regression analysis
using the three different doses of rhDNAse and adjusting for
the t40FEV1 did not find any apparent dose-related effect
on pulmonary function (data not shown).Hospitalization and follow-up
The hospitalization rates in the placebo group (45%) and in
the rhDNAse group (63%) did not differ significantly
(p > 0.05). After adjustment for FEV1 at time 40 min,Adjusted FEV1 values Post Drug Administration
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Figure 2 Change in FEV1 over 6 h treatment period and 24 h
follow-up for both investigational product and placebo. FEV1
data was adjusted for pre-intervention values. Error bars
indicate the standard error of the mean.
Table 3 Percent predicted FEV1 for post-ED arrival times by rhDNAse use and severity at time 40 min post-ED arrival*.
Minutes post-ED arrival FEV1 > 39% predicted FEV1  39% predicted Interaction between
drug and severity
p-value
placebo N Z 12 rhDNAse N Z 13 placebo n Z 8 rhDNAse N Z 17
Time 60 52.0  9.3 49.1  8.1 28.8  4.9 34.7  6.0 0.045
Time 120 55.5  12.5 51.2  8.7 30.8  6.3 37.8  7.6 0.039
Time 180 54.9  12.7 54.8  10.2 31.9  6.9 41.0  8.8 ns
Time 240 54.8  11.9 55.8  11.3 33.5  6.9 42.4  9.1 ns
Time 360 56.8  13.9 54.0  10.8 33.9  8.6 42.5  10.1 ns
Time 24 h 50.0  13.7 42.5  12.8 32.5  8.8 37.6  12.7 ns
*Data was partitioned and analyzed into two groups based on the median FEV1 at time 40 min (pre-randomization value). Please see text
for details.
1100 R.A. Silverman et al.hospitalization risk for patients receiving rhDNAse did not
differ significantly from placebo patients (OR 2.16 (95% CI
0.63e7.34)). Time 24 h spirometry measures were obtained
in 44/50 patients. After adjustment for FEV1 at time 40, the
meanFEV1 in the placebo groupwas 42.9% and in the rhDNAse
group was 40.1% (p > 0.05). In addition, there were no
differences between the groups for relapse at day 7.Safety
There were 2/30 patients in the rhDNAse group and 0/20 in
the placebo group with more than a 10% decrease in FEV1 at
the first study assessment point following the study inter-
vention (time 60 min). In one patient who received 2.5 mg
rhDNAse the FEV1 changed from 36% predicted at time
40 min to 31% at 60 min; the time 360 min FEV1 was 39%
predicted. The FEV1 in another patient who received 5.0 mg
rhDNAse went from 60% predicted at time 40 min to 36% at
60 min. This patient had a past history of multiple intuba-
tions and after study completion she indicated prior
episodes of severe bronchospasm after receiving any type
of nebulized therapy. She continued in the study and by
time 120 min her FEV1 was 52% predicted and at 240 min
FEV1 was 59% predicted. There were no other clinically
significant adverse effects noted in other patients during
the study.-8
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Figure 3 Difference of means (drug minus placebo) for each
dosing level of investigational product compared to placebo
group over the 6 h treatment period and for the 24 h follow-up.
Data was adjusted for pre-randomization values.Discussion
We explored whether a single dose of nebulized rhDNAse
improved pulmonary function in non-intubated severely
obstructed Emergency Department asthmatics refractory to
standardized bronchodilator therapy. Overall rhDNAse did
not cause significant improvement in FEV1 at any of the
post-randomization time points. rhDNAse did not have an
impact on need for hospitalization or on the FEV1 24 h after
randomization.
When we evaluated data from patients with more severe
obstruction, those receiving rhDNAse tended to have more
improvement in pulmonary function especially at the
earlier time points, but small sample size and multiple
exploratory analyses limit interpretation of these findings.
There are a number of published case reports of patients
with life-threatening asthma who were failing conventional
management and responded to rhDNAse either by direct
intratracheal instillation8; direct instillation of rhDNAse via
bronchoscope10,14; and in a case of an intubated pregnant
asthmatic, nebulization via the endotracheal tube.15 In
a case-series of 8 intubated asthmatic children, intra-
tracheal rhDNAse followed by percussive physiotherapy
improved ventilation.16 Three other cases of non-intubated
children responding to nebulized rhDNAse have also been
reported.9
One previous clinical trial evaluating rhDNAse has been
published.11 Among 121 children with acute moderate to
severe asthma, 5.0 mg of nebulized rhDNAse did not
improve asthma scores or the need for hospitalization.
There was a slightly better trend to improved asthma scores
in the rhDNAse group at the 60 and 120 min post-
randomization time points; this was not statistically
significant. There were no previous published clinical trials
evaluating rhDNAse in adults.
The rationale for attempting to reverse mucous plugging
in severe acute asthma is supported by autopsy studies.
Extensive airway obstruction by exudate containing both
mucus and cells is characteristic of fatal asthma
episodes4,17 with plugging involving large and small
airways.18 Airway exudates are composed of mucin, plasma
proteins, DNA and a mixture of inflammatory and epithelial
cells. Cellular material has been found to be as important
as mucus and protein exudates in luminal occlusion of fatal
obstructive asthma,4 especially in smaller airways.
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plugging was an important factor in severe airway
compromise, and that patients with the most extensive
mucous plugging would benefit the most from rhDNAse.
Since we had no direct means to identify the extent of
mucous plugging in an ED setting, the lack of response to
bronchodilator therapy was used as an indicator of airway
plugging. This provided a practical means of testing our
hypothesis in non-intubated patients, but did not provide
certainty regarding the contribution of plugging to the
acute episode and this remains a study limitation. Future
studies may consider using 24 h response to systemic
steroids and continued usage of bronchodilator therapy as
an alternative method of selecting patients with presumed
mucous plugging.
Factors potentially influencing the efficacy of rhDNAse
include the content of DNA relative to other substances (eg
mucin) that contribute to the viscosity of the plug, and the
size and location of the mucous plug. We did not know
whether the amount of DNA contained in the mucous of
patients with severe asthma was sufficient to allow reversal
of mucous plugging after treatment with rhDNAse. Sputum
from asthmatics have higher DNA content than sputum from
non-asthmatics.19 While the DNA content is much higher
in pulmonary secretions from cystic fibrosis patients
compared to patients with chronic stable asthma, it is
possible patients with acute but non-fatal asthma would
have higher sputum DNA content than individuals with
chronic stable asthma. However, we did not find any pub-
lished studies which evaluated DNA content of airway plugs
in patients surviving a severe episode.
We also assumed (but had no way to prove) enough
nebulized drug would reach occluded airways to promote
expectoration of the plug. Presumably much higher
amounts of drug reach the sites of plugging when installed
via the intratracheal route or bronchoscopic visualization,
and more plug could be removed when mechanical suction
is applied compared to the cough mechanism. This study
limitation can be addressed in future studies by testing
repeated dosing strategies in the most severely ill non-
intubated patients, or through a trial involving intubated
patients.
Regarding safety, in two patients a 10% drop in FEV1
occurred immediately following administration of rhDNAse
which subsequently increased with beta-agonist therapy.
Since most participants, including those with more severe
obstruction, had improvement soon after receiving rhDNAse
we cannot determine whether the drop in FEV1 was inci-
dental or whether we identified a subgroup of patients with
drug induced bronchoconstriction. In addition, we noted
a non-significant trend for increased hospitalization and
lower FEV1 at 24 h in patients who received rhDNAse. One
possible explanation is patients subsequently randomized
to rhDNAse had a lower FEV1 on ED arrival (before admin-
istration of rhDNAse), and they reverted back to the lower
baseline after completion of aggressive ED bronchodilator
therapy. Further study is needed to determine whether
these findings are due to chance randomization or the drug
itself.
In summary, rhDNAse did not improve airway obstruction
in non-intubated ED patients with severe asthma refractory
to bronchodilators. Slightly greater improvement in FEV1was found among patients with lower initial FEV1 but small
sample size and multiple analyses limit interpretation of
these findings. This study does not support routine usage of
rhDNAse in patients with very severe acute asthma, but
rather identifies a subgroup of patients where the use of
rhDNAse could be further studied.
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